Short answer
ACADIA PHARMACEUTICALS INC (ACAD) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 furnished under Regulation FD and generally excluded from Section 18 “filed” liability.
ACADIA PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 furnished under Regulation FD and generally excluded from Section 18 “filed” liability
- Exhibit not incorporated by reference into other Securities Act or Exchange Act filings absent specific reference
Item 8.01 · Other Events
- 60 mg remlifanserin improved SAPS-H+D versus placebo at week 6, but primary endpoint missed nominal significance: p=0.0603
- CGI-S-ADP favored 60 mg, effect size 0.37 with nominal p=0.0077
- Favorable safety profile, with adverse events and discontinuations similar to placebo and no QT prolongation signal
- Company continuing two Phase 3 studies while removing the 30 mg dose arm
- Phase 2 results scheduled for oral presentation at CTAD on November 16-19, 2026
Item EX-99.1 · Exhibit EX-99.1
- Phase 2 primary endpoint narrowly missed: SAPS-H+D change -12.6 vs -10.4 placebo, p=0.0603
- Key secondary CGI-S-ADP favored 60 mg: change -1.3 vs -0.9 placebo, nominal p=0.0077
- Acadia continuing two Phase 3 ADP studies while removing the ineffective 30 mg dose
- Favorable safety profile, with adverse events and discontinuations similar to placebo and no QT prolongation signal
- Detailed results due at the CTAD conference November 16-19, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACADIA PHARMACEUTICALS INC 8-K filings
Get the next ACAD 8-K as it lands
Follow ACAD for push alerts, or ask the research agent what this filing means.